2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160509
    BTB 06061 652967-47-0 98%
    BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease.
    BTB 06061
  • HY-160529
    α7 nAChR Modulator-2 98%
    α7 nAChR Modulator-2 (Compound 7b) is a α7 nAChR positive allosteric modulator (PAM) with an EC50 of 2.1 μM. α7 nAChR Modulator-2 can be used for the research of cognitive disorders.
    α7 nAChR Modulator-2
  • HY-160548
    mTOR inhibitor-18 2170358-67-3 98%
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    mTOR inhibitor-18
  • HY-160588
    Nav1.8-IN-7 2761181-58-0 98%
    Nav1.8-IN-7 (Example 116) is a selective Nav1.8 inhibitor. Nav1.8-IN-7 shows an inhibition of >50% with 100 nM for Nav1.8. Nav1.8-IN-7 inhibits hERG with an IC50 of 15.6 μM. Nav1.8-IN-7 has the potential for pain research.
    Nav1.8-IN-7
  • HY-160589
    Nav1.8-IN-8 2626945-23-9 98%
    Nav1.8-IN-8 (Compound A11) is a Nav1.8 channel inhibitor. Nav1.8-IN-8 may prevent associated diseases mediated by sodium ion channels (NaV).
    Nav1.8-IN-8
  • HY-160591
    Nav1.8-IN-10 2664047-95-2 98%
    Nav1.8-IN-10 (Compound 6) is a Nav1.8 channel inhibitor. When the concentration is 4 nM, the percentage blocking rate of Nav1.8 channel is 79.4%. Nav1.8-IN-10 can be used in the study of pain disorders.
    Nav1.8-IN-10
  • HY-160592
    Nav1.8-IN-11 2990578-70-4 98%
    Nav1.8-IN-11 (Example 1) is a Nav1.8 channel inhibitor with a IC50 value of 0.1 nM. Nav1.8-IN-11 can be used in the study of pain disorders.
    Nav1.8-IN-11
  • HY-160593
    Nav1.8-IN-12 3029020-84-3 98%
    Nav1.8-IN-12 (Compound 23 R) is a Nav1.8 channel inhibitor. Nav1.8-IN-12 can be used in the study of pain-related diseases.
    Nav1.8-IN-12
  • HY-160616
    LPA5 antagonist 3 1664336-44-0 98%
    LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC50 of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis.
    LPA5 antagonist 3
  • HY-160617
    SIRT2-IN-14 1884571-59-8 98%
    SIRT2-IN-14 (Compound 78) is a selectve inhibitor for SIRT2 with an IC50 of 0.196 μM.
    SIRT2-IN-14
  • HY-160637
    Lp-PLA2-IN-17 1818842-74-8 98%
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2.
    Lp-PLA2-IN-17
  • HY-160655
    SERT-IN-3 289717-03-9 98%
    SERT-IN-3 (compound 12) is an inhibitor of serotonin transporter (SerT). In pharmacological assays, the IC50 of SERT-IN-3 for SerT was 34.4 nM.
    SERT-IN-3
  • HY-160656
    5-HT/NA Reuptake inhibitor-1 844882-78-6 98%
    5-HT/NA Reuptake inhibitor-1 (compound 9) is a selective dual 5-HT and NA reuptake inhibitor with IC50 of 660 nM and 70 nM respectively. . 5-HT/NA Reuptake inhibitor-1 has good in vitro human metabolic stability, hERG selectivity and passive membrane permeability.
    5-HT/NA Reuptake inhibitor-1
  • HY-160663
    Nav1.7 blocker 1 1426336-36-8 98%
    Nav1.7 blocker 1 (example 41) is a Na+ channel (Nav) blocker with an IC50 value of 0.037 μM. Nav1.7 blocker 1 can be used for the study of pain, including neuropathic pain, postoperative pain, inflammatory pain, and so on.
    Nav1.7 blocker 1
  • HY-160668
    Histamine H3 antagonist-1 1000392-25-5 98%
    Histamine H3 antagonist-1 (Compound 10o) is a histamine H3 antagonist and a serotonin reuptake inhibitor, which can be used in depression research.
    Histamine H3 antagonist-1
  • HY-160677
    P2X4 antagonist-2 2055601-24-4 98%
    P2X4 antagonist-2 is an antagonist for P2X4 with an IC50 of 24 nM.
    P2X4 antagonist-2
  • HY-160955
    Z218484536 1223877-07-3 98%
    Z218484536 is a selective and brain-penetrant phosphoserine phosphatase (PSPH) inhibitor. Z218484536 binds to PSPH with a Kd value of approximately 0.23 μM. Z218484536 reduces L-serine and D-serine levels in astrocytes. Z218484536 is able to suppress spontaneous epileptic seizures without causing serious side effects. Z218484536 also shows good anti-epileptic effects in the temporal lobe epilepsy (TLE) model.
    Z218484536
  • HY-160959
    AN317 946074-35-7 98%
    AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP+. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB).
    AN317
  • HY-160978
    Timelotem 96306-34-2 98%
    Timelotem (KC-7507 free base) is a representative of a class of 1, 2-cyclo1, 4-benzodiazepines. Timelotem shows significant antipsychotic properties. Timelotem produces sedative, anti-anxiety and anti-convulsant effects by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA). Timelotem can be used in studies of schizophrenia and other mental disorders.
    Timelotem
  • HY-160980
    Sornidipine 95105-77-4 98%
    Sornidipine is a calcium channel blocker. Sornidipine also reduces neurogenic inflammation. Sornidipine reduces the inflow of calcium ions into cells by blocking L-type calcium channels, thereby reducing the contraction of vascular smooth muscle, leading to vasodilation and decreased blood pressure. Sornidipine can be used to study the cardiovascular system especially in hypertension and related cardiovascular diseases.
    Sornidipine
Cat. No. Product Name / Synonyms Application Reactivity